BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26286589)

  • 41. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer.
    Kuo CS; Liu CY; Pavlidis S; Lo YL; Wang YW; Chen CH; Ko HW; Chung FT; Lin TY; Wang TY; Lee KY; Guo YK; Wang TH; Yang CT
    Front Immunol; 2018; 9():232. PubMed ID: 29483918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.
    Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH
    Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
    Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M
    Tumori; 2014; 100(1):60-8. PubMed ID: 24675493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.
    Guo NL; Dowlati A; Raese RA; Dong C; Chen G; Beer DG; Shaffer J; Singh S; Bokhary U; Liu L; Howington J; Hensing T; Qian Y
    EBioMedicine; 2018 Jun; 32():102-110. PubMed ID: 29861409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic modifications in
    Wei Y; Liang J; Zhang R; Guo Y; Shen S; Su L; Lin X; Moran S; Helland Å; Bjaanæs MM; Karlsson A; Planck M; Esteller M; Fleischer T; Staaf J; Zhao Y; Chen F; Christiani DC
    Clin Epigenetics; 2018; 10():41. PubMed ID: 29619118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decreased expression of FOXF2 as new predictor of poor prognosis in stage I non-small cell lung cancer.
    Kong PZ; Li GM; Tian Y; Song B; Shi R
    Oncotarget; 2016 Aug; 7(34):55601-55610. PubMed ID: 27487137
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003.
    Morgensztern D; Waqar S; Subramanian J; Gao F; Trinkaus K; Govindan R
    J Thorac Oncol; 2012 Oct; 7(10):1479-84. PubMed ID: 22982648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
    She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
    JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
    Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
    Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non-small cell lung cancer.
    Gharabaghi MA
    Clin Respir J; 2018 Feb; 12(2):633-638. PubMed ID: 27768839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
    Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
    Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.
    Zhang J; Gold KA; Lin HY; Swisher SG; Xing Y; Lee JJ; Kim ES; William WN
    J Thorac Oncol; 2015 Apr; 10(4):682-90. PubMed ID: 25590605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
    Wang K; Li Y; Wang J; Chen R; Li J
    Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
    Liu J; Ping W; Zu Y; Sun W
    Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer.
    Zhang C; Min L; Zhang L; Ma Y; Yang Y; Shou C
    Tumour Biol; 2016 Feb; 37(2):2193-207. PubMed ID: 26349752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer.
    Huang JQ; Liang HL; Jin TE; Xie Z
    Int J Clin Exp Pathol; 2015; 8(9):11278-86. PubMed ID: 26647102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.